Publications by authors named "Lyndsay Watkins"
Article Synopsis
- Multiple myeloma (MM) is a type of cancer that affects plasma cells, and it's often resistant to common treatments, especially in advanced stages with genetic mutations in the RAS pathway.
- Researchers developed a mouse model called VQ MM to study this advanced form and screened 147 FDA-approved anti-cancer drugs, finding that the combination of trametinib (Tra) and ponatinib (Pon) was particularly effective, prolonging survival in mice.
- However, ponatinib negatively impacted the function of CD8 T cells, which are important for immune response, suggesting that while it enhances treatment effects, it may also reduce immune response, highlighting the need for balanced therapy approaches.
Background And Purpose: Members of the GPCR family are targeted by a significant fraction of the available FDA-approved drugs. However, the physiological role and pharmacological properties of many GPCRs remain unknown, representing untapped potential in drug design. Of particular interest are ~100 less-studied GPCRs known as orphans because their endogenous ligands are unknown.
View Article and Find Full Text PDFG protein coupled receptors (GPCRs) are the main mediators of signal transduction in the central nervous system. Therefore, it is not surprising that many GPCRs have long been investigated for their role in the development of anxiety and mood disorders, as well as in the mechanism of action of antidepressant therapies. Importantly, the endogenous ligands for a large group of GPCRs have not yet been identified and are therefore known as orphan GPCRs (oGPCRs).
View Article and Find Full Text PDF